22.418 articles found

[Diagnosis and therapy of Parkinson's disease].

Wittstock M, Benecke R.

MMW Fortschr Med · 2005-05-01

PMID: 15968869

[Current treatment of Parkinson's disease: problems and controversies].

Burkhard PR, Villemure JG, Vingerhoets FJ.

Rev Med Suisse · 2005-05-01

PMID: 15977710

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

Paija O, Laine K, Kultalahti ER, Leinonen M, Huupponen R, Gordin A, Reinikainen K.

Clin Neuropharmacol · 2005-05-01

DOI: 10.1097/01.wnf.0000166393.33781.87PMID: 15965309

New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease

WALTER RAINER, ANDERSKEWITZ RALF, KLEY JOERG, DOLLINGER HORST, GOEGGEL ROLF, JUNG BIRGIT, MACK JUERGEN, NICKOLAUS PETER.

· 2005-04-28

METHOD OF SCREENING THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE

YOSHIMOTO Yasuki, SHIMODA Taiji.

· 2005-04-27

Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases

GMEINER PETER, HUBNER HARALD, SCHLOTTER KARIN.

· 2005-04-27

Adult stem cell therapy beyond haemopoietic stem cell transplantation? An update.

Hows J.

Transpl Immunol · 2005-04-26

DOI: 10.1016/j.trim.2005.03.010PMID: 15982566

Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.

Lu L, Zhao C, Liu Y, Sun X, Duan C, Ji M, Zhao H, Xu Q, Yang H.

Brain Res Brain Res Protoc · 2005-04-22

DOI: 10.1016/j.brainresprot.2005.03.002PMID: 15878150

Therapeutic role of coenzyme Q(10) in Parkinson's disease.

Shults CW.

Pharmacol Ther · 2005-04-21

DOI: 10.1016/j.pharmthera.2005.02.002PMID: 15963354

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

Valkovic P, Benetin J, Blazícek P, Valkovicová L, Gmitterová K, Kukumberg P.

Parkinsonism Relat Disord · 2005-04-20

DOI: 10.1016/j.parkreldis.2005.01.007PMID: 15878587

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

Camarda R, Camarda C, Grimaldi S, Camarda LK, Monastero R, Gangitano M.

J Neurol · 2005-04-14

DOI: 10.1007/s00415-005-0818-8PMID: 15822002

Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.

Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G.

J Neurol · 2005-04-13

DOI: 10.1007/s00415-005-0830-zPMID: 15809822